Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients
Open Access
- 18 May 2015
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 67 (10) , 1345-1353
Abstract
Objective: Simplified measures to quantify rheumatoid arthritis (RA) disease activity are increasingly used. The minimum clinically important differences (MCID) for some measures, such as the Clinical Disease Activity Index (CDAI), have not been well‐defined in real‐world clinic settings, especially for early RA patients with low/moderate disease activity.Methods: Data from Canadian Early Arthritis Cohort patients were used to examine absolute change in CDAI in the first year after enrollment, stratified by disease activity. MCID cut points were derived to optimize the sum of sensitivity and specificity versus the gold standard of patient self‐reported improvement or worsening. Sensitivity, specificity, positive predictive values, and negative predictive values were calculated against patient self‐reported improvement (gold standard) and for change in pain, Health Assessment Questionnaire (HAQ), and Disease Activity Score in 28 joints (DAS28) improvement. Discrimination was examined using the area under receiver operator curves. Similar methods were used to evaluate MCIDs for worsening for patients who achieved low disease activity.Results: A total of 578 patients (mean ± SD age 54.1 ± 15.3 years, 75% women, median [interquartile range] disease duration 5.3 [3.3, 8.0] months) contributed 1,169 visit pairs to the improvement analysis. The MCID cut points for improvement were 12 (patients starting in high disease activity: CDAI >22), 6 (moderate: CDAI 10–22), and 1 (low disease activity: CDAI <10). Performance characteristics were acceptable using these cut points for pain, HAQ, and DAS28. The MCID for CDAI worsening among patients who achieved low disease activity was 2 units.Conclusion: These minimum important absolute differences in CDAI can be used to evaluate improvement and worsening and increase the utility of CDAI in clinical practice.Keywords
Funding Information
- The Canadian Early Arthritis Cohort (CATCH)
- Amgen and Pfizer Canada
- Hoffmann-LaRoche
- UCB Canada
- Bristol-Myers Squibb Canada
- AbbVie
- Johnson & Johnson Innovative Medicine
- NIH (AR-064172, 1UH2-AR-067691-01)
- Agency for Healthcare Research and Quality (HS-018517)
- Pilot Project Award from the Patient Centered Outcomes Research Institute (IP2-PI000737)
- Cedar Hill Foundation
This publication has 29 references indexed in Scilit:
- Incidence and predictors of secondary fibromyalgia in an early arthritis cohortAnnals of the Rheumatic Diseases, 2013
- Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 TrialThe Journal of Rheumatology, 2012
- 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care & Research, 2012
- Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohortArthritis Care & Research, 2011
- The Minimally Important Difference for Patient-reported Outcomes in Spondyloarthropathies including Pain, Fatigue, Sleep, and Health Assessment QuestionnaireThe Journal of Rheumatology, 2010
- Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritisRheumatology, 2009
- Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baselineArthritis Care & Research, 2009
- Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohortAnnals of the Rheumatic Diseases, 2007
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995